ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Over the past two decades, ABL1 tyrosine kinase inhibitors (TKIs) have led to marked improvements in the overall survival outcomes of patients with chronic myeloid leukemia in the chronic phase (CML‐CP) [1].